2Harold C. Safety of cefepime :a new extended-spectrum parenteral cephalosporin. Am J Med,1996,100(Suppl 6A) :68s-75s.
3Comely OA, Bethe U, Seifert H, et al. A randomized monocentric trial in febrile neutropen patients:ceftriaxone and gentamicin vs cdepime and gentamicin. Ann Hemato1,2002 ,81:37-43.
4Egerer G, Goldschwidt H, Streich N, et al. Cegtutidinm in combination with glycopeptide antibiotic is an effetive first-fine therapy for patients undergoing hige-dose therapy with autologous peripheral blood stem cell support. Support Care Cancer, 1999,7:336-342.
6Giancarlo A,Albano DF,Pasquale P,et al. Cephalospvain-induced hypoprothrombinemia:ls the N-methylthiotetrazole side chain the culprit?Antimicro Agents Chemothera, 1986,29 : 1108-1109.
7Schafer H,Naber K,Adam D. Hemostasis distttrbanee caused by cephalosporins with an N-methylthiotetrazole side chain. A randomized pilot study. Arzneimittelforshung, 1989,39 : 1156-1162.
8Gabryelewice A, Prokopawicz J, Wolosowicz N, et al. Changes in some hemostatic parameters in patients with infections treated with cefttaidime and latamoxef. Folia Haemotol Int Meg Klin Morphol Blufforsh, 1987,114:398-407.
9Weitekamp MR,Caputo GM,Al-Mondhlry HR,et al. The effects of cefoperazone on plate.let ruction and coagulation in normal volunteers. J Antimicro Chemother, 1985,16:95-101.
10Weitekamp MR, Abet RC. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA, 1983,249: 69-71.
